Abstract
BRCA1 is a tumour suppressor gene implicated in the predisposition to early onset breast and ovarian cancer. We have generated cell lines with inducible expression of BRCA1 to evaluate its role in mediating the cellular response to various chemotherapeutic drugs commonly used in the treatment of breast and ovarian cancer. Induction of BRCA1 in the presence of Taxol and Vincristine resulted in a dramatic increase in cell death; an effect that was preceded by an acute arrest at the G2/M phase of the cell cycle and which correlated with BRCA1 mediated induction of GADD45. A proportion of the arrested cells were blocked in mitosis suggesting activation of both a G2 and a mitotic spindle checkpoint. In contrast, no specific interaction was observed between BRCA1 induction and treatment of cells with a range of DNA damaging agents including Cisplatin and Adriamycin. Inducible expression of GADD45 in the presence of Taxol induced both G2 and mitotic arrest in these cells consistent with a role for GADD45 in contributing to these effects. Our results support a role for both BRCA1 and GADD45 in selectively regulating a G2/M checkpoint in response to antimicrotubule agents and raise the possibility that their expression levels in cells may contribute to the toxicity observed with these compounds.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Amundson SA, Zhan Q, Penn LZ, Fornace AJ . 1998 Oncogene 17: 2149–2154
Anderson AF, Schlegel BP, Nakaajima T, Wolpin ES, Parvin JD . 1998 Nat. Genet. 19: 254–256
Chapman MS, Verma IM . 1996 Nature 382: 678–679
Cortez D, Wang Y, Qin J, Elledge SJ . 1999 Science 286: 1162–1166
Dumontet C, Sikic BI . 1999 J. Clin. Oncol. 3: 1061–1070
Futamura M, Arakawa H, Matsuda K, Katagiri T, Saji S, Miki Y, Nakamura Y . 2000 Cancer Res. 60: 1531–1535
Gayther SA, Pharoah PD, Ponder BA . 1998 Neoplasia 4: 365–376
Gowen LC, Avrutskaya AV, Latour AM, Koller BH, Leadon SA . 1998 Science 281: 1009–1012
Haber D . 2000 Lancet. 355: 2090–2091
Harkin DP, Bean JM, Miklos D, Song Y-H, Truong VB, Englert C, Christians FC, Ellisen LW, Maheswaran S, Oliner JD, Haber DA . 1999 Cell 97: 575–586
Hollander MC, Sheikh MS, Bulavin DV, Lundgren K, Augeri-Henmueller L, Shehee R, Molinaro TA, Kim KE, Tolosa E, Ashwell JD, Rosemberg M, Zhan Q, Fernandez-Salguero PM, Morgan WF, Deng C-X, Fornace Jr AJ . 1999 Nature Genetics 23: 176–184
Houvras U, Benezra M, Zhang H, Manfredi JJ, Weber BL, Licht JD . 2000 J. Biol. Chem. 275: 36230–36237
Hsu L-C, White RL . 1998 Proc. Natl. Acad. Sci. USA 95: 12983–12988
Jin SJ, Hongcheng Z, Fan F, Blanck P, Fan W, Colchagie AB, Fornace Jr AJ, Zhan Q . 2000 Oncogene 19: 4050–4057
Larson JS, Tonkinson JL, Lai MT . 1997 Cancer Res. 57: 3351–3355
Leadon SA, Avrutskaya AV . 1997 Cancer Res. 57: 3784–3791
Lee JS, Collins KM, Brown AL, Lee CH, Chung JH . 2000 Nature 404: 201–204
Li S, Ting NS, Zheng L, Chen PL, Ziv Y, Shiloh Y, Lee EY, Lee WH . 2000 Nature 406: 210–215
MacLachlan TK, Somasundaram K, Sgagias M, Shifman Y, Muschel RJ, Cowan KH, El-Deiry WS . 2000 J. Biol. Chem. 275: 2777–2785
Marquis ST, Rajan JV, Wynshaw-Boris A, Xu J, Yin GY, Abel KJ, Weber BL, Chodosk LA . 1995 Nat. Genet. 1: 17–26
McGowan CH, Russell P . 1993 EMBO J. 12: 75–85
Moynahan ME, Chiu JW, Koller BH, Jasin M . 1999 Mol. Cell. 4: 511–518
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katchrt H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A, Skolnick MH . 1994 Science 266: 66–71
Monteiro AN, August A, Hanafusa H . 1996 Proc. Natl. Acad. Sci. USA 93: 13595–13599
Ouchi T, Monteiro AN, August A, Aaronson SA, Hanafusa H . 1998 Proc. Natl. Acad. Sci. USA 95: 2302–2306
Ouchi T, Lee SW, Ouchi M, Aaronson SA, Horvath CM . 2000 Proc. Natl. Acad. Sci. USA 97: 5208–5213
Ruffner H, Verma IM . 1997 Proc. Natl. Acad. Sci. USA 94: 7138–7143
Schmidt M, Lu Y, Liu B, Fang M, Mendelsohn J, Fan Z . 2000 Oncogene 19: 2423–2429
Scully R, Anderson SF, Chao DM, Wei W, Ye L, Young RA, Livingston DM, Parvin JD . 1997a Proc. Natl. Acad. Sci. USA 94: 5605–5610
Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, Ashley T, Livingston DM . 1997b Cell 88: 265–275
Somasundaram K, Zhang H, Zeng YX, Houvras Y, Peng Y, Zhang H, Wu GS, Licht JD, Weber BL, El-Deiry WS . 1997 Nature 389: 187–190
Wang Q, Zhang H, Kalino K, Green MI . 1998 Oncogene 17: 1939–1948
Wang XW, Zhan Q, Coursen JD, Khan MA, Kontny HU, Yu L, Hollander MC, O'Conner PM, Fornace AJ, Harris CC . 1999 Proc. Natl. Acad. Sci. USA 96: 3706–3711
Wang XW, Zhan Q, Coursen JD, Khan MA, Kontny HU, Yu L, Hollander MC, O'Conner PM, Fornace Jr AJ, Harris CC . 1999 Proc. Natl. Acad. Sci. USA 96: 3706–3711
Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ, Qin J . 2000 Genes. Dev. 14: 927–939
Wong AK, Ormonde PA, Pero R, Chen Y, Lian L, Salada G, Berry S, Lawrence Q, Dayananth P, Ha P, Tavtigian SV, Teng DH, Bartel PL . 1998 Oncogene 17: 2279–2285
Xu X, Weaver Z, Linke SP, Li C, Gotay J, Wang XW, Harris CC, Ried T, Deng CX . 1999 Mol. Cell. 3: 389–395
Yu X, Wu LC, Bowcock AM, Aronheim A, Baer R . 1998 J. Biol. Chem. 273: 25388–25392
Zhan Q, Antinore MJ, Wang XW, Carrier F, Smith ML, Harris CC, Fornace AJ . 1999 Oncogene 18: 2892–2900
Zheng L, Li S, Boyer TG, Lee W-H . 2000 Oncogene 19: 6159–6175
Zhong Q, Chen CF, Li S, Chen Y, Wang CC, Xiao J, Chen PL, Sharp ZD, Lee WH . 1999 Science 285: 747–750
Acknowledgements
This work was supported by grants from the Ulster Cancer Foundation, Action Cancer and the Breast Cancer Campaign.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mullan, P., Quinn, J., Gilmore, P. et al. BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene 20, 6123–6131 (2001). https://doi.org/10.1038/sj.onc.1204712
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204712
Keywords
This article is cited by
-
Bag-1 silencing enhanced chemotherapeutic drug-induced apoptosis in MCF-7 breast cancer cells affecting PI3K/Akt/mTOR and MAPK signaling pathways
Molecular Biology Reports (2019)
-
Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein
Cancer Chemotherapy and Pharmacology (2018)
-
Analysis of ZNF350/ZBRK1 promoter variants and breast cancer susceptibility in non-BRCA1/2 French Canadian breast cancer families
Journal of Human Genetics (2013)
-
Drug therapy for hereditary cancers
Hereditary Cancer in Clinical Practice (2011)
-
Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells
Cancer Chemotherapy and Pharmacology (2011)